Biomea Fusion (BMEA) Stock: Buy, Sell, or Hold?
BMEA - Biomea Fusion, Inc. Common Stock
$1.74
-0.06 (-3.33%)
âŧ
5d:
-5.69%
30d:
+28.89%
90d:
+50.0%
WAIT
LOW Confidence
Analysis Updated: Sep 16, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When BMEA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BMEA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BMEA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BMEA is currently trading at $1.74, which is considered slightly high relative to its 30-day fair value range of $1.38 to $1.85.
Technical Outlook: Technically, BMEA is in a downtrend. Immediate support is located at $1.66, while resistance sits at $2.07. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: BMEA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.50 (+273.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BMEA is in a downtrend. Immediate support is located at $1.66, while resistance sits at $2.07. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: BMEA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.50 (+273.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.38 -
$1.85
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 273.6% below Wall St target ($6.50)
- WARNING: Composite score 34/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.38 -
$1.85
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.66
Resistance Level
$2.07
Current Trend
Downtrend
Technical data as of
Sep 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.85
Wall Street Target
$6.50
(+273.6%)
Share & Embed Analysis
Last updated: September 17, 2026 1:26 AM ET
Data refreshes hourly during market hours. Next update: 2:26 AM
Data refreshes hourly during market hours. Next update: 2:26 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMEA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 46 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 40 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 47 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$48 | 41 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$137 | 56 HOLD |
